Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

3292 Study Matches

Sorting by: Relevance Distance

Discovering Digital Biomarkers Linked to Opioid Use Disorder

A Study to Evaluate Digital Biomarkers Linked to Opioid Use Disorder

Tyler Oesterle
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303682-H01-RST
21-001383
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Diagnosed with Opioid Use Disorder (OUD).
  • Willing to participate and follow medication-assisted treatment (MAT) program rules.
  • Willing to wear a watch and answer questionnaires.


Exclusion Criteria:
 

  • Active untreated comorbid mental health symptoms.
  • Unable to understand or sign informed consent.
  • History of heart disease.
  • Women currently pregnant.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Bone Health in Patients With and Without Adrenal Disease

Bone Health in Patients with/without Adrenal Disease

Irina Bancos
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303683-H01-RST
21-001396
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult ≥ 18 years old.
  • Diagnosis of either of the following conditions:
    • adrenal adenoma;
    • macro- or micronodular hyperplasia with available or planned dexamethasone suppression test result;
    • ACTH-dependent Cushing syndrome;
    • No adrenal disorder (as referent subject).
  • Ability to provide consent.


Exclusion Criteria:
 

  • Individual < 18 years of age.
  • Inability to provide consent.
  • Exogenous Cushing syndrome,

Eligibility last updated 3/10/22. Questions regarding updates should be directed to the study team contact.

Adrenal cancer, Cushing syndrome, Fracture, Osteoporosis, Osteopenia
Endocrine system, Fracture of bone, Macronodular adrenal hyperplasia, Micronodular adrenal hyperplasia, Musculoskeletal system, Osteopenia, Adrenal adenoma, Osteoporosis
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Biomarker guided Electroconvulsive therapy for Superior Treatment outcomes in patients with mood disorders (BEST-Mood)

A Study to Evaluate Garmin Wearables for Patients Receiving Electroconvulsive Therapy

Paul Croarkin
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303688-H01-RST
21-001413
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Aged 18 years or older.
  • Outpatient or inpatient status.
  • Patients who have been clinically referred for ECT and completed the clinical informed consent process for ECT.
  • Patients who had the capacity to consent for ECT independently on a voluntary basis.
  • Healthy control patients will be aged 18 years or older and have the capacity to consent for the research study.


Exclusion Criteria:
 

  • Patients who are undergoing court ordered ECT are not eligible for the study.
  • Patients who did not have the capacity to consent for clinical ECT are not eligible.
  • Patients who in the opinion of the clinical principal investigator (Dr. Croarkin) or a psychiatrist study team member are not able to consistently wear the Garmin device or complete protocol related activities.
  • Healthy control patients who have active psychiatric symptoms based on an interview with the principal investigator (Dr. Croarkin) or a psychiatrist study team member are not eligible to participate. 
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD (CSP-00006)

A Study to Evaluate RheOx Bronchial Rheoplasty System to Treat Chronic Bronchitis in Adults with COPD

Ryan Kern
All
35 years and over
Not Applicable, Early Feasibility
This study is NOT accepting healthy volunteers
2021-303692-P01-RST
21-002659
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


1. Patient is at least 35 years of age.

2. Patient has chronic bronchitis, defined as productive cough for three months in each
of two successive years, whereas other causes of productive cough have been ruled out.

3. Patient has a CAT score ≥ 10.

4. Patient has an SGRQ score ≥ 25.

5. Patient's responses to the first two questions of the CAT instrument sum to ≥ 7 points
or the sum is 6 points and the patient's total CAT score is > 20 points.

6. Patient has FEV1/FVC < 0.7.

7. Patient has a pre-procedure post-bronchodilator FEV1 percent predicted of ≥ 30%.

8. Patient is receiving guideline directed pharmacotherapy which includes one or more
long acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for
at least 8 weeks prior to randomization

9. Patient has a cigarette smoking history of at least ten pack years.

10. In the opinion of the Primary investigator, patient is able to undergo 2
bronchoscopies under general anesthesia and is able to adhere to the study follow-up
schedule


Exclusion Criteria:


1. Patient has known unresolved lower respiratory tract infection (e.g., pneumonia,
mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).

2. Patient has a steroid-dependent condition requiring >10 mg of oral corticosteroid per
day.

3. Patient has any implantable electronic device (e.g., pacemaker, cardioverter
defibrillator, neuro-stimulation devices).

4. Patient has a history of arrhythmia within past two years which includes tachy-atrial
arrhythmias, any ventricular tachy-arrhythmias, or sinus bradycardia with heart rate
less than 45 beats per minute.

5. Patient has unresolved lung cancer.

6. Patient has a pulmonary nodule or cavity that in the judgement of the Primary
investigator may require intervention during the course of the study.

7. Patient had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung
implant/prosthesis, metal airway stent, valves, coils or bullectomy. Prior
pneumothorax without lung resection, pleural procedures without surgery, or
segmentectomy are acceptable.

8. Patient has emphysema of greater than or equal to 20% as quantified on baseline HRCT
scan (low attenuation area less than -950HU) as determined by the CT Core Lab.

9. Patient has asthma based on Global Initiative for Asthma (GINA) criteria.

10. Patient has clinically significant bronchiectasis influencing the patient's clinical
symptoms of cough and phlegm.

11. Patient has actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.)
within the last 6 months.

12. Patient is unable to walk over 225 meters in 6 minutes.

13. Patient has a serious medical condition that, in the Primary investigator's opinion,
could compromise patient safety or confound the interpretation of the patient's
response to therapy (e.g., congestive heart failure, cardiomyopathy, or myocardial
infarction in the past year, renal failure, liver disease cerebrovascular accident
within the past 6 months, uncontrolled diabetes (HbA1c >8%), uncontrolled hypertension
(diastolic BP >100mmHg) or autoimmune disease requiring treatment with
immunosuppressant medications or a disease requiring chemotherapy).

14. Patient has uncontrolled GERD.

15. Patient has known severe pulmonary hypertension.

16. Patient has a known sensitivity to medication required to perform bronchoscopy (i.e.,
lidocaine, atropine, benzodiazepines).

17. Patient is pregnant, nursing, or planning to get pregnant during study duration.

18. Patient is currently participating in another clinical study involving an
investigational product

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/29/22. Questions regarding updates should be directed to the study team contact.

Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Quality of Life Outcomes After Subtotal Petrosectomy and Ear Canal Closure for Cholesteatoma: A Retrospective Study (ECC)

A Study to Evaluate Quality of Life Outcomes for Cholesteatoma

Matthew Carlson
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303721-H01-RST
21-001587
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults, ≥ 18 years of age.
  • Have undergone subtotal petrosectomy and ear canal closure with or without bone conduction hearing aid implantation for cholesteatoma/chronic otitis media since 1/1/2020.


Exclusion Criteria:
 

  • Individuals < 18 years of age.
  • Subtotal petrosectomy and ear canal closure for other diagnoses, surgical intervention before 1/1/2000.
  • Patients who do not desire to complete the survey.
  • Patients who do not sign the study’s HIPAA Authorization form.
     
Cholesteatoma, Middle ear disease, Middle ear infection
Cholesteatoma, Chronic otitis media, Hearing implant surgery
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The Predictive Capabilities of Exhaled Volatile Organic Compounds (VOCs) on Heart Failure Status: A Pilot Study (HFVOC)

Exhaled Biomarkers for Heart Failure

Bruce Johnson
All
21 years and over
This study is NOT accepting healthy volunteers
2021-303723-H01-RST
21-001574
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults over the age of 21 and who are willing and able to give informed consent.
  • Diagnosed with CHF and presenting to Mayo Clinic for HF clinic visits.
  • Classified as NYHA Class I-IV within the past 12 months.


Exclusion Criteria:
 

  • Under the age of 21.
  • Physical or cognitive limitations that would prevent patient from applying or using the device properly.
  • Women who are known to be pregnant or plan to become pregnant within the course of this study.
  • Has known allergies to silicone based adhesive or skin breakdown in areas where device placement is required.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Time Longitudinal Study of the Microbiome in Colorectal Cancer Subjects

Time Longitudinal Study of the Microbiome in Colorectal Cancer Subjects

Nicholas Chia
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303747-H01-RST
21-001536
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • 18 years of age or older.
  • Patients undergoing bowel resection by any standard surgical approach.


Exclusion Criteria:

  • Female who is pregnant.
  • Currently receiving or have received pelvic cancer radiation therapy in the past 2 weeks.
  • Currently receiving or have received chemotherapy in the past 2 weeks.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

An Open-Label Extension Study for Patients with Dravet Syndrome Who Previously Participated in Studies of STK-001 (Swallowtail)

A Study to Evaluate Patients with Dravet Syndrome Who Previously Participated in Studies of STK-001

Elaine Wirrell
All
30 months and over
Phase 1/2
This study is NOT accepting healthy volunteers
2021-303748-P01-RST
21-001955
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patient must be ≥ 2.5 years of age.
  • Patient and/or authorized representative must be willing and able to give informed consent/assent and any authorizations required by local law for participation in the study.
  • Patient and their caregiver must be willing and able (in the Investigator’s opinion) to comply with all protocol requirements.
  • Patient must have completed dosing with STK-001 and the End of Study Visit in Study STK-001-DS-101, with an acceptable safety profile per Investigator judgment.
  • Patient must have satisfactory compliance with study visits and procedures in Study STK-001-DS-101 per Investigator and Sponsor judgment.
  • Patient must meet age-appropriate institutional standard practices for intrathecal (IT) drug administration procedures.
  • Patient and/or family (or caretaker) must be sufficiently fluent in English or Spanish to be able to complete questionnaires relevant to this study.
  • Patient must have completed Study STK-001-DS-101 within 4 weeks of the start of their participation in Study STK-001-DS-501, unless approved by the Sponsor.


Exclusion Criteria:

  • Patient has met any withdrawal criteria from Study STK-001-DS-101.
  • Patient is currently being treated as maintenance therapy with an antiepileptic drug acting primarily as a sodium channel blocker including phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, or rufinamide.
  • Patient has clinically significant unstable medical conditions other than epilepsy.
  • Patient has had clinically relevant symptoms or a clinically significant illness (in the judgment of the Investigator) at Screening or prior to dosing on Day 1, other than epilepsy.
  • Patient has a spinal deformity or other condition that may alter the free flow of CSF or has an implanted CSF drainage shunt.
  • Patient has clinically significant (in the judgment of the Investigator) abnormal laboratory values at baseline or prior to dosing on Day 1.
  • Patient has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3-fold upper limit of normal (ULN), serum creatinine > ULN or platelet count < lower limit of normal at baseline and upon repeat testing.
  • Patient has clinically significant abnormalities (in the judgment of the Investigator) in the 12-lead ECG measured at Screening/Baseline (This includes 12-lead ECG from STK-001-DS-101 [Visit 6 or Visit 9], if STK-001-DS-101 Visit 6 or Visit 9 and STK-001-DS-501 Visit 1 are the Same Day).
  • Patient has a psychiatric or behavioral disorder which, in the opinion of the Investigator, may interfere with the patient’s participation in the study.
  • Patient is currently taking, or within 4 weeks prior to Screening/Baseline has taken any anticoagulant (including but not limited to heparins, warfarin and other vitamin K antagonists, dabigatran, rivaroxaban and apixaban), or within 7 days prior to Screening/Baseline, has taken any antiplatelet (including but not limited to aspirin, non-steroidal anti-inflammatory drugs, clopidogrel, ticlopidine. and dipyridamole).
  • Patient is a female of childbearing potential, or patient is a fertile male with female partner(s) of childbearing potential, unless willing to ensure that they or their partners use effective contraception throughout the duration of the study and for at least 6 months after their last dose of STK-001.
  • . Patient is a female who is lactating or planning pregnancy during the duration of the study and for at least 6 months after their last dose of STK-001.
  • Patient has any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, may influence the results of the study, or may affect the patient’s ability to participate in the study.
  • Patient has been treated (or is being treated) with an investigational product (other than STK-001) since participating in Study STK-001-DS-101.
  • Patient is participating in an observational study, unless approved by the Sponsor.
Drug, Drug therapy, Intrathecal injection
Epilepsy, Seizure
Nervous system, Severe myoclonic epilepsy in infancy
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Minnesota Spinal Cord Injury Data Network

Minnesota Spinal Cord Injury Data Network

Kristin Zhao
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303749-H01-RST
21-001639
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • ≥ 18 years of age.
  • Presence of an external traumatic event that results in a spinal cord injury, including surgical procedures, radiation, and medical complications.
  • Temporary or permanent loss of sensory and/or motor function as a result of the traumatic event.
  • Admission to the database within one year of injury.
  • If patient is discharged as Minimal Deficit or Recovered, they must be hospitalized in the system for at least one week before discharge.
  • Discharge from the system as:
    • Having completed inpatient acute rehabilitation;
    • Achieving a neurologic status of normal or minimal deficit;
    • Deceased.
  • Reside in the geographic catchment area of the system (greater Minnesota, Iowa, North Dakota, South Dakota, and western Wisconsin) at the time of the injury. Patients may be injured outside of the catchment area.
  • A US citizen or non-US citizen who is expected to stay in the catchment area.


Exclusion Criteria:
 

  • Completion of an organized rehabilitation program prior to the admission to the system.
  • Patients who are discharged as deceased.
Spinal cord injury
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The Application of Voice Enabled Artificial Intelligence for the Diagnosis of Hepatic Encephalopathy (Voice AI)

A Study to Evaluate Voice-enabled Artificial Intelligence to Diagnosis Hepatic Encephalopathy

Douglas Simonetto
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303761-H01-RST
21-001699
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female, age ≥ 18 years old.
  • Having hepatic encephalopathy (HE).
  • Are in the hospital (Methodist or St. Marys). Consented in an exam room or hospital room
  • Must be able to carry on a conversation.
  • Ability of subject or caregiver to provide written, informed consent. (LAR needed if subject is HE)
  • Cirrhosis of any etiology.


Exclusion Criteria:

  • Individual < 18 years old.
  • Known history of voice disorder or surgery that may alter voice characteristics.
  • Smoking or vaping use currently or within the last 3 months
  • Severe chronic obstructive pulmonary disease
  • Inability to speak.
  • Upper respiratory tract infection within the last week.
  • Acute alcohol intoxication.
  • VHI-10 score greater than 11.
  • West Haven Criteria Grade 4.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Impact of Ketamine versus Propofol for Anesthetic Induction on Acute Kidney Injury and Renal Biomarkers in Cardiac Surgery (KKICS)

Ketamine and Kidney Injury in Cardiac Surgery

Erica Wittwer
All
70 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2021-303772-H01-RST
21-004327
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age greater than or equal to 70 years.
  • Presenting for cardiac surgery at the Mayo Clinic in Rochester, Minnesota. 
  • Scheduled to undergo complex cardiac surgery. Complex cardiac surgery will be defined as surgery involving more than one heart valve, redo-sternotomy procedures, or combined valvular and CABG procedures.


Exclusion Criteria:

  • Left or right ventricular assist device implantation or explantation.
  • Procedures not requiring cardiopulmonary bypass.
  • Active infection or sepsis.
  • Severe hepatic disease or ascites.
  • Pre-operative renal dysfunction including a baseline creatinine equal to or greater than 1.5 mg/dL or requiring dialysis.
  • Immunosuppressive medication use (including steroid use), immunodeficiency syndrome, known neurologic or psychiatric disorder, or use of drugs for psychosis.

 

 

 

We will include patients age greater than or equal to 70 years presenting for cardiac surgery at the Mayo Clinic in Rochester, Minnesota.  Patients will be eligible for inclusion if they are schedule to undergo complex cardiac surgery. Complex cardiac surgery will be defined as surgery involving more than one heart valve, redo-sternotomy procedures, or combined valvular and CABG procedures. Exclusion criteria will include left or right ventricular assist device implantation or explantation, procedures not requiring cardiopulmonary bypass, active infection or sepsis, severe hepatic disease or ascites, pre-operative renal dysfunction including a baseline creatinine equal to or greater than 1.5 mg/dL or requiring dialysis, immunosuppressive medication use (including steroid use), immunodeficiency syndrome, known neurologic or psychiatric disorder, or use of drugs for psychosis.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery (CP2018-1)

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Juan Crestanello
All
18 years and over
Pivotal
This study is NOT accepting healthy volunteers
2021-303779-P01-RST
21-001790
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Subject is greater than or equal to 18 years of age.
  • Subject has history of persistent or long-standing persistent atrial fibrillation:
    • AF documentation requirement for persistent AF: Physician’s note indicating continuous AF > 7 days but no more than 1 year, and electrocardiographic documentation showing continuous AF within 90 days of the ablation procedure. Documentation can include a 24- hour holter (or equivalent) or two ECGs taken at least seven days apart within 90 days of the ablation procedure;
    • AF documentation requirement for longstanding persistent AF: physician’s note indicating at least 1 year of continuous AF, and electrocardiographic documentation showing continuous AF within 90 days of the ablation procedure. Documentation can include a 24- hour holter (or equivalent) or two ECGs taken at least seven days apart within 90 days of the ablation procedure. The performance of a successful cardioversion (sinus rhythm > 30 seconds) within 12 months of an ablation procedure with documented early recurrence of AF within 30 days should not alter the classification of AF as long-standing persistent.
  • Stable Subject that is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Tricuspid valve repair or replacement, Coronary artery bypass procedures, patent foramen ovale repair, and/or atrial septal defect.
  • Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 90 days of enrollment as documented in patient medical history).
  • Subject is willing and able to provide written informed consent.
  • Subject has a life expectancy of at least 5-years.
  • Subject is willing and able to return for scheduled follow-up visits.


Exclusion Criteria:

  • Stand-alone AF without indication(s) for concomitant CABG and/or valve surgery.
  • Previous surgical Maze procedure.
  • Wolff-Parkinson-White syndrome or other Supra-Ventricular arrhythmia, AV nodal reentry.
  • Prior cardiac surgery (Redo).
  • Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or patent foramen ovale repair, and/or atrial septal defect repair.
  • Class IV NYHA heart failure symptoms.
  • Prior history of cerebrovascular accident within 6 months or at any time if there is residual neurological deficit.
  • Documented ST elevation MI within the 6 weeks prior to study enrollment.
  • Need for emergent cardiac surgery (i.e., cardiogenic shock).
  • Known carotid artery stenosis greater than 80%.
  • Documented (continuous) AF duration of greater than ten years.
  • LA diameter > 7 cm by TTE within 12 weeks (90 days) of procedure.
  • Current diagnosis of active systemic infection.
  • Severe peripheral arterial occlusive disease defined as claudication with minimal exertion.
  • Renal failure requiring dialysis or hepatic failure.
  • A known drug and/or alcohol addiction.
  • Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study.
  • Pregnancy or desire to get pregnant within 12-months of the study treatment.
  • Preoperative need for an intra-aortic balloon pump or intravenous inotropes.
  • Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia.
  • Subjects who have been treated with thoracic radiation.
  • Subjects in current chemotherapy.
  • Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases).
  • Subjects with known connective tissue disorders.
  • Subjects with known hypertrophic obstructive cardiomyopathy.
  • Subjects with known cold agglutinin.
  • Patient has a condition that in the opinion of the investigator, may jeopardize the patient’s wellbeing and/or the soundness of this clinical study.
  • Subject has a contraindication to post-operative anticoagulation; Patient has history of blood dyscrasia or clotting disorder (i.e., Idiopathic Thrombocytopenic Purpura [ITP] or Thrombotic Thrombocytopenic Purpura [TTP]).

Eligibility last updated 9/21/21. Questions regarding updates should be directed to the study team contact.

Device
Atrial fibrillation, Heart arrhythmia
Cardiovascular system, Longstanding persistent atrial fibrillation, Persistent atrial fibrillation
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Developing Novel Tools for Determining Risk of Respiratory Complications Following Hematopoietic Stem Cell Transplant

A Study to Develop Novel Tools for Post-HCT Respiratory Complications

Hemang Yadav
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303794-P01-RST
21-000913
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult patients (age ≥ 18 years old).
  • Undergoing evaluation for autologous or allogeneic bone marrow transplant (HCT) at Mayo Clinic Rochester.
  • Scheduled for pre-HCT pulmonary function test by the primary team.


Exclusion Criteria:
 

  • Limited mobility requiring use of gait aid or wheelchair.
  • Fall risk.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Impact of Menopause on Cardiac Stiffness Acquired with Magnetic Resonance Elastography

A Study to Evaluate the Impact of Menopause on Cardiac Stiffness Acquired with Magnetic Resonance Elastography

Arvin Forghanian-Arani
All
21 years to 53 years old
This study is NOT accepting healthy volunteers
2021-303801-H01-RST
21-001823
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Aim 1

  • Healthy, normal subjects around the approximate age of menopause (~ 51).
  • In the 40-60 year age range without known cardiac conditions.
  • Without symptoms referable to the heart, namely chest pain or shortness of breath. 

Aim 2

  • Subjects from the ongoing “Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women after Bilateral Oophorectomy: A Randomized Controlled Trial” study.  
  • Subjects in this cohort will be between 21 and 45 years of age, at the onset of the study.
  • Willingness to return for follow up exam +/- 3 weeks of 12 month post-operative follow-up appointment.
  • These subjects will undergo two cardiac MRI/MRE exams one with-in +/- three weeks of their bilateral oophorectomy surgery and with-in +/- three weeks of their 12 month follow-up appointment.


Exclusion Criteria:
 

  • Known cardiac conditions, symptoms referable to the heart; namely, chest pain or shortness of breath. 
  • For Magnetic Resonance Imaging (MRI) participants:
    • Absolute contraindications to MRI including pacemaker, AICD device, cochlear implant, VP shunt, aneurysm clip, deep brain stimulator, or severe claustrophobia;
    • Body weight over 500 pounds (or 226 kilograms), and chest/waist/hip circumference over 160 cm, due to MRI system limit (70-cm bore, < 400 lbs.).
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository- HS PROGRESS

Hidradenitis Suppurativa Registry

Afsaneh Alavi
All
10 years and over
This study is NOT accepting healthy volunteers
2021-303810-H01-RST
21-001797
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female, ≥ 10 years of age.
  • Diagnosis of Hidradenitis Suppurativa (HS) by a dermatologist or practitioner experienced in making a diagnosis of HS.
  • Written informed consent (and assent when applicable) obtained from subject or subject’s legal representative and ability for subject to comply with the requirements of the study.
  • Immediate family members (for saliva and genetics data).


Exclusion Criteria:

  • Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Learning from Our Patients, Learning from Our Practice: Implementing an Intervention to Support Patients on Dialysis

Learning from Our Patients, Learning from Our Practice: Implementing an Intervention to Support Patients on Dialysis

Kasey Boehmer
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2021-303832-H01-RST
21-001884
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Clinician Participants

  • Clinicians employed at Mayo Clinic who provide care to patients visiting the Mayo Clinic Department of Nephrology and Hypertension Dialysis Services.

Patient Participants

  • Adult patients (18 years of age and older).
  • Receive long-term dialysis treatment and services at Mayo Clinic.


Exclusion Criteria:

  • Minors (under the age of 18 years).
  • Non-English speaking.
  • Lack the ability to provide informed consent.
Other, Behavioral
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Evaluating the Need and Impact of a Multifaceted Wellness Program on the Health Related Quality of Life (HRQOL), Disease Activity, and Healthcare Utilization in Female Patients with Inflammatory Bowel Disease: Phase II – The Impact (IBD and WHC II)

IBD and Women's Health Intervention

Laura Raffals
Female
18 years to 64 years old
Not Applicable
This study is NOT accepting healthy volunteers
2021-303837-H01-RST
21-002100
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Female patient with a diagnosis of Ulcerative Colitis (UC) or Crohn’s Disease (CD) seen in the IBD clinic in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester.
  • Who are between 18-64 years of age.
  • Ability to provide informed consent.
  • Ability to complete all aspects of this trial.


Exclusion Criteria:
 

  • Female patients with a diagnosis of UC or CD with medical co-morbidity or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
  • Participation in another organized wellness program.
Behavioral
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Comparative Quality of Life Assessment between Internal Endoscopic versus Percutaneous Drainage of Benign and Malignant Biliary Obstruction (QoL)

A Quality of Life Assessment of Patients with Biliary Obstruction Undergoing Endoscopic or Percutaneous Drainage

Andrew Storm
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303842-H01-RST
21-000142
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients with benign biliary obstruction.
  • Patients with malignant biliary obstruction.
  • Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) and/or percutaneous transhepatic biliary drainage (PTBD).


Exclusion Criteria:
 

  • Patients with gallstone disease.
  • Patients who will undergo ERCP who currently have a percuteanous biliary drain placed.
  • Patients who will undergo PTBD who currently have a biliary stent placed.
  • Female patients who are pregnant.
  • Prisoners and other vulnerable populations.

Eligibility last updated 10/12/21. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies

A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer

Andrea Wahner Hendrickson
All
18 years and over
Phase 1
This study is NOT accepting healthy volunteers
2021-303850-P01-RST
21-001959
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
  • Patients must have histologically confirmed uterine serous carcinoma with at least one lesion suitable for biopsy without significant risk to the patient.  Patient disease must be evaluable or measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Biopsiable lesion can be same as evaluable lesion.
  • Patients must have had at least one prior line of cytotoxic chemotherapy. Patients can have received an unlimited number of additional lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy
  • Patients must have HER2-positive or HER2-expressing tumors determined by a CLIA-certified laboratory. Specific requirement of HER2 status is outlined below:
    • HER2 1-3 + expression by IHC; OR
    • HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH); OR
    • If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible.
  • Patients must have archival FFPE tissue available for central confirmation of HER2 testing.
  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of DS-8201a in combination with olaparib in patients < 18 years of age, children are excluded from this study.
  • ECOG performance status ≤ 1 (Karnofsky ≥ 70%).
  • Patients must have adequate organ and marrow function within 14 days of randomization/enrollment as defined below:
    • Hemoglobin ≥ 10.0 g/dL;
    • Absolute neutrophil count ≥ 1,000/mcL**;
    • Platelets ≥ 100,000/mcL*;
    • Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN), (< 3 × ULN in the presence of documented Gilbert’s syndrome or liver metastases at baseline);
    • AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN;
    • International Normalized ratio ≤ 1.5 × ULN (INR)/Prothrombin time (PT) and activated partial thromboplastin time (aPTT);
    • Creatinine ≤ 1.5 × institutional ULN OR;
    • Glomerular filtration rate (GFR) ≥ 51 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2). 
    • *No transfusions with red blood cells or platelets are allowed within 1 week prior to screening assessment.
    • **No administration of G-CSF is allowed within 1 week prior to screening assessment.
  • Patients must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization/enrollment.
  • Patients who are Human Immunodeficiency Virus (HIV) positive may participate IF they meet the following eligibility requirements:
    • They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective.
    • They must have an undetectable viral load and a CD4 count ≥ 250 cells/µL within 7 days of enrolment.They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months.
    • HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with brain metastases should be stable and off steroids and at least 4 weeks from radiation at the time of registration.
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be better than class 2B.
  • The effects of DS-8201a and olaparib on the developing human fetus are unknown. For this reason and because HER2 antibody conjugated to a topoisomerase 1 inhibitor agents as well as PARP inhibitors are known to be teratogenic; thus, women of childbearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 7 months (WOCBP only) after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of DS-8201a and olaparib administration. For methods considered as highly effective methods of contraception.
  • Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol < 40 pg/mL [<147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  • Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrolment in this study.
  • Female subjects must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible.


Exclusion Criteria:

  • Patients who have had chemotherapy (including antibody drug therapy) within 4 weeks with the following exceptions: 1 week for weekly paclitaxel; 2 weeks or five half-lives, whichever is longer, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, hormonal agents; or 6 weeks for nitrosoureas or mitomycin C.
  • Patients who have had radiation therapy within 4 weeks.
  • Patients who have had a major surgery within 4 weeks.
  • Patients who are receiving any other investigational agents.
  • For the dose expansion cohort: Patients who have received prior PARP inhibitors.
  • Patients with a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Patients with clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (i.e., Rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior pneumonectomy.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to DS-8201a, the inactive ingredients in the drug product, olaparib, or severe hypersensitivity to other monoclonal antibodies.
  • Patients receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
  • Patients with a medical history of myocardial infarction within 6 months before randomization/enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association Class IIb to IV), troponin levels consistent with myocardial infarction as defined according to the manufacturer 28 days prior to randomization.
  • Patients with a corrected QT interval (QTc) prolongation to > 470 ms (females) or > 450 ms (males) based on average of the screening triplicate 12-lead ECG.
  • Patients with clinically significant corneal disease in the opinion of the Investigator.
  • Patients with multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, and other solid tumors curatively treated.
  • Patients with an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  • Patients receiving chloroquine or hydroxychloroquine will require a washout period of ≥ 14 days to be eligible for the study.
  • Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade ≤ 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee (e.g., grade 2 chemotherapy-induced neuropathy).
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because DS-8201a is a HER2 antibody conjugated to a topoisomerase 1 inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DS-8201a, breastfeeding should be discontinued if the mother is treated with DS-8201a. These potential risks may also apply to other agents used in this study.

Eligibility last updated 8/26/21. Questions regarding updates should be directed to the study team contact.

 

Biologic/Vaccine, Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

EvALuation of ECG transmission and AI moDels using Apple watch ECGs and Symptoms data collected usiNg a Mayo iPhone App (ALIGN)

EvALuation of ECG transmission and AI models using Apple watch ECGs and symptoms data collected usiNg a Mayo iPhone App

Paul Friedman
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303851-H01-RST
21-001964
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult patients, ≥ 18 years of age.
  • Using the Mayo patient iPhone app. (determined automatically via Mayo software).


Exclusion Criteria:

  • Inability to provide informed consent.
  • Age under 18 years.

 

 

 

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) (ABAGART)

A Study to Evaluate Abatacept to Treat Giant Cell Arteritis

Kenneth Warrington
All
50 years and over
Phase 3
This study is NOT accepting healthy volunteers
2021-303854-P01-RST
21-001986
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • A diagnosis of newly-diagnosed or relapsing Giant Cell Arteritis (GCA).
  • Diagnostic criteria for GCA.
  • A patient will be said to have GCA by meeting 3 of 5 of the following modified ACR criteria for the classification of GCA in which 1 of the 3 must consist of criteria 4 or 5:
    • Age at disease onset ≥ 50 years;
    • New onset or new type of localized pain in the head;
    • ESR of > 40 mm in the first hour by the Westergren method or CRP measurement above the laboratory normal limit;
    • Temporal artery abnormality (i.e., temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries);
    • Temporal artery or large vessel biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant celor an abnormal temporal artery ultrasound showing features consistent with active giant cell arteritis (“halo sign”) or characteristic changes of large vessel stenosis or aneurysm by arteriography.
  • GCA with evidence of active disease (defined below) present within the past 8 weeks.
  • They must be willing and able to comply with treatment and follow-up procedures.
  • Both women and men who are of child-bearing potential must be willing to use an effective means of birth control while receiving treatment through this study. Effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or hormonal contraception.
  • Must be willing and able to provide written informed consent.


Exclusion Criteria:

  • Evidence of a recent acute infection defined as:
    • Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics.
    • Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy.
  • Patients with history of chronic or recurrent bacterial infection (such as chronic pyelonephritis, osteomyelitis, and bronchiectasis etc.).
  • Patients with a history of recurrent herpes zoster (more than 1 episode) or disseminated (more than 1 dermatome) herpes zoster or disseminated herpes simplex, or ophthalmic zoster. Symptoms of herpes zoster or herpes simplex must have resolved more than 60 days prior to screening.
  • Patients with a history of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis).
  • Patients with a history of primary immunodeficiency.
  • Patients at risk for tuberculosis (TB) defined as follows:
    • Current clinical, radiographic or laboratory evidence of active TB, even if currently being treated.  Chest x-rays (posterior/anterior and lateral) obtained within the 6 months prior to screening and TB testing (IFN- gamma release assay or PPD) performed in the past month prior to screening will be accepted; however, a copy of the reports must be placed in the participant binder;
    • A history of active TB unless there is documentation that the patient had received prior anti-TB treatment that was appropriate in duration and type according to local health authority guidelines;
    • Patients with a positive TB screening test indicative of latent TB will not be eligible for the study unless they:
      • Have no evidence of current TB based on chest x-ray performed during the screening period and by history and physical exam, and
      • They are currently being treated for latent TB or the site has documentation of successful prior treatment of latent TB. Treatment regimens should be dictated by local guidelines as long as the treatment dose and duration meet or exceed local health authority guidelines. If permitted by local guidelines regarding treatment with biologic medications, patients with latent TB may be randomized prior to completion of treatment as long as they have completed at least 4 weeks of treatment and they have no evidence of current TB on chest x-ray at screening.
  • Patients who are pregnant or who are nursing infants.
  • Inability to comply with study guidelines.
  • Cytopenia: platelet count < 80,000/mm³, total White Blood Count (WBC) < 3,000/mm³ (3 x 10⁹/L) absolute neutrophil <1500/mm³, hematocrit < 20%.
  • Renal insufficiency defined by a creatinine clearance of less than or equal to 20 ml/min.
  • AST or ALT > 3 times above normal laboratory range.
  • Other severe, progressive, or uncontrolled disease that in the investigator’s opinion could prevent a patient from fulfilling the study requirements or that would increase the risk of study participation.
  • Patients who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Patients who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
  • Receipt of an investigational agent or device within 30 days prior to enrollment.
  • A live vaccination within 3 months before randomization.
  • Patients on non-biologic immunosuppressants must discontinue these medications before randomization (azathioprine, mycophenolate mofetil, mycophenolic acid, leflunomide, hydroxychloroquine, cyclosporin, tacrolimus, or other conventional immunosuppressive agent).
  • Patients who had received an alkylating agent such as cyclophosphamide must discontinue these medications at least 8 weeks before randomization.
  • Patients who have been treated within 4 weeks of randomization with etanercept or within 8 weeks with adalimumab, certolizumab, golimumab, or infliximab.
  • Patients who have been treated within 8 weeks of randomization with anti-IL-6 agents (e.g., tocilizumab, sirukumab) or a janus kinase inhibitor.
  • Patients who have been treated within 4 weeks of randomization with anakinra.
  • Patients who have received prior treatment with rituximab within the past 6 months prior to randomization.
  • Patients who have received prior treatment with abatacept or CTLA4-Ig.
  • Patients who will require oral or IV glucocorticoid treatment during the trial for conditions other than GCA.
  • Hypersensitivity to abatacept and/or its excipients.
  • Presence of any of the following disease processes:
    • Takayasu arteritis;
    • Granulomatosis with polyangiitis;
    • Microscopic polyangiitis;
    • Eosinophilic granulomatosis with polyangiitis (Churg-Strauss);
    • Polyarteritis nodosa;
    • Cogan’s syndrome;
    • Behçet’s disease;
    • Sarcoidosis;
    • Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics vasculitis;
    • Cryoglobulinemic vasculitis;
    • Systemic lupus erythematosus;
    • Rheumatoid arthritis;
    • Mixed connective tissue disease or any overlap autoimmune syndrome.
Drug, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Remote Monitoring in Cancer Care: A Platform Study

A Study to Evaluate Remote Monitoring in Cancer Care

Jonas Paludo
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303868-P01-RST
21-002043
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Provide written informed consent.
  • Patients undergoing commercial CAR-T cell therapy in an outpatient setting.

​​​​​​


Exclusion Criteria:

  • Individuals < 18 years of age.
  • Non-English speaking.
  • Planned initiation of lymphodepleting chemotherapy in the inpatient setting.

 

Cancer, Leukemia, Lymphoma
Biological therapy for cancer, Cancer treatment, Cellular therapy, Hematopoietic system, Malignant neoplastic disease, Medical Oncology, Telemedicine
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy

Optimizing Pancreatic Cancer Management Using Next Generation Imaging and Liquid Biopsy

Ajit Goenka
All
18 years to 99 years old
This study is NOT accepting healthy volunteers
2021-303885-P01-RST
21-001716
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults ≥ 18 years with treatment-naïve biopsy-proven PDA or with findings diagnostic for PDA on baseline imaging (CT, MRI or PET).
  • Localized disease expected to undergo surgical resection following NAT.
  • ECOG performance status of 0-2.
  • Ability to provide informed consent.


Exclusion Criteria:
 

  • Non-PDA histology on biopsy.
  • No baseline PET/CT or PET/MRI.
  • Histopathologically proven metastatic PDA.
  • Non-FDG avid PDA on baseline PET/CT or PET/MRI.
  • Pregnant women.

Eligibility last updated8/25/21.  Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

SLEep Apnea in Heart Failure with Preserved Ejection Fraction - Exercise Capacity and Impact of Positive Airway Pressure Therapy (SLEEP-HFpEF)

A Study to Evaluate Exercise Capacity and Positive Airway Pressure Impact on Sleep Apnea in Heart Failure

Yogesh Reddy
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303886-H01-RST
21-002139
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Diagnosis of HFpEF by catheterization with resting PCWP > 15 mmHg or exercise PCWP > 25 mmHg.
  • If no known diagnosis of OSA, must not be pacemaker dependent with with either atrial pacing or VVI without sinus rhythm.
  • If no known diagnosis of OSA, must be able to temporarily hold nitrates or alpha channel blockers for home WatchPAT testing.


Exclusion Criteria:

  • Ejection fraction < 40%.
  • Obstructive hypertrophic cardiomyopathy.
  • Constrictive pericarditis or tamponade.
  • Active myocarditis.
  • Complex congenital heart disease.
  • Other valve disease requiring surgical intervention.
  • Terminal illness (other than HF) with expected survival of less than 1 year.
  • Inability to comply with planned study procedures.
  • Pregnancy or breastfeeding mothers.

Eligibility last updated 5/9/22. Questions regarding updates should be directed to the study team contact.

     

    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Phase 2 Lymphoma Epidemiology of Outcomes Cohort - Central IRB (LEO 2.0)

    A Study to Evaluate Lymphoma Epidemiology

    James Cerhan
    All
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-303896-P01-RST
    21-001804
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Patients must be newly diagnosed within 6 months (180 days) of enrollment.
    • Patients may have been treated as long as initial non-Hodgkins Lymphoma (NHL) or Hodgkin's Lymphoma (HL) diagnosis is within 6 months of enrollment.
    • Patients must be 18 years or older.
    • Patients will be recruited regardless of human immunodeficiency virus (HIV) status.


    Exclusion Criteria:

    • Patients less than 18 years of age.
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Phase 2 Lymphoma Epidemiology of Outcomes Cohort - Central IRB (LEO 2.0)

    A Study to Evaluate Lymphoma Epidemiology

    James Cerhan
    All
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-303896-P01-MAIJ
    21-001804
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Patients must be newly diagnosed within 6 months (180 days) of enrollment.
    • Patients may have been treated as long as initial non-Hodgkins Lymphoma (NHL) or Hodgkin's Lymphoma (HL) diagnosis is within 6 months of enrollment.
    • Patients must be 18 years or older.
    • Patients will be recruited regardless of human immunodeficiency virus (HIV) status.


    Exclusion Criteria:

    • Patients less than 18 years of age.
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic Health System — Mankato, MN

    Validation of Shear Wave Elastography and 3D Ultrasound as Surrogate Measurement of Tissue Properties and Injury Diagnostic Tool for the ACL

    Ultrasound as Surrogate Diagnostic Tool for ACL Injury

    Jacob Sellon
    All
    14 years to 40 years old
    This study is NOT accepting healthy volunteers
    2021-303907-H01-RST
    21-002175
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Subjects recruited for the injured limb cohort may be dual-recruited as controls so long as their contralateral limb satisfies the inclusion criteria.
    • Age between 14-40 years old.
    • No history of prior knee trauma or knee surgery.
    • No hard tissue structural damage to the knee joint concomitant to the ACL injury.
    • No abnormality that adversely impacts standard function of the knee. For the injured cohort, an acute ACL injury confirmed by MRI is required.
    • For the healthy cohort, no history of structural knee damage in the target limb is required.


    Exclusion Criteria:

    • Less than 14 and over 40 years of age.
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Characterization of microvasculature in kidney transplant by super-resolution ultrasound imaging

    Ultrasound Microvessel Imaging of Transplant Kidney

    Shigao Chen
    All
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-303918-H01-RST
    21-002208
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Male and female patients.
    • Age ≥ 18 years old.
    • Having transplant kidney and undergoing clinically indicated allograft biopsy.
    • Able and willing to consent.


    Exclusion Criteria:

    • Patients lacking capacity to consent.
    • Vulnerable subjects such as prisoners, pregnant women, nursing mothers.
    • Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents.
    Transplanted kidney present
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    A First In Human Evaluation of a Novel Approach to Painless Cardioversion (NAPC) in Patients with Atrial Fibrillation (MediCool)

    MediCool Protocol

    Juan Crestanello
    All
    18 years and over
    Not Applicable
    This study is NOT accepting healthy volunteers
    2021-303924-P01-RST
    21-002221
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Subject must be ≥ 18 years or older.
    • Male or female.
    • Subject has documented paroxysmal, or persistent atrial fibrillation (AF) with a history of less than one-year duration.
    • Must be in AF at time of surgery, or inducible using manual or electrical stimulation.
    • Subject is willing and able to provide written informed consent.
    • Subject has a life expectancy of at least 1 year.


    Exclusion Criteria:

    • Long-standing AF (duration > 1 year).
    • Prior AF ablation.
    • Left main coronary artery occlusion > 70%.
    • Critical aortic stenosis (gradient > 50mm HG).
    • Inability to induce patient into AF without drugs at time of surgery.
    • Female subjects who are pregnant at time of surgery.
    • Subjects with a medical condition or comorbidity that could adversely impact study participation, safety or conduct of the study.
    • Permanent pacemaker or implantable cardioverter defibrillator.
    • Current cancer treatment that includes radiation of the heart.
    • Inability to give informed consent.
    Device, Atrial cardioversion, Other
    Atrial fibrillation, Heart arrhythmia
    Cardiovascular system, Cardioversion, Paroxysmal atrial fibrillation, Persistent atrial fibrillation
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Mayo MRI White-Matter-Nulled Imaging Study (START MRI)

    Mayo MRI White-Matter-Nulled Imaging Study

    Gregory Worrell
    All
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-303929-H01-RST
    21-002308
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Provision of signed and dated informed consent form.
    • Stated willingness to comply with all study procedures and availability for the duration of the study.
    • Male or female, 18 years of age or older.
    • In good general health as evidenced by medical history but may include a diagnosis of epilepsy.
    • Volunteers who are confirmed to have temporal lobe epilepsy based on established medical history and have established outpatient epilepsy care within the Mayo Clinic Health System.


    Exclusion Criteria:

    • Participants with a contraindication to MRI. Such contraindications include, but are not limited to: pacemaker, metallic cardiac valve(s), magnetic material such as surgical clips, tattoos, implanted electronic infusion pumps or any other condition that would interfere with the MRI, a stent somewhere in the body, a history of allergic reaction to any metals.
    • Participants who have structural anatomical legions outside the medial temporal lobe.
    • Pregnancy or lactation.
    • Participants who report previous experience with claustrophobia, anxiety and/or vertigo when moved inside the scanner.
    • Febrile illness within the last thirty days.
    • Treatment with another investigational drug or other intervention within the last thirty days.
    • Subjects incapable of giving informed written consent.
    •  Participants in the prisoner population.

    Eligibility last updated 8/26/21. Questions regarding updates should be directed to the study team contact.

     

    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN